Access Inequities and System Capacity for Lymphoma Care in Latin America: Results From the Grupo de Estudio Latinoamericano de Linfoproliferativos Consortium
Authors:
- 1 November 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (11)
Abstract
Purpose: The integration of diagnostic tools, immunochemotherapy, targeted agents, and cellular therapies such as chimeric antigen receptor T-cell therapy (CAR-T) cells has transformed lymphoma outcomes in high-income countries. However, in Latin America (LATAM), access to these advances remains limited. This study aimed to assess lymphoma care access and institutional capacity in LATAM. Methods: We conducted a cross-sectional digital survey from July 2025 to August 2025, coordinated by the Grupo de Estudio Latinoamericano de Linfoproliferativos network. The survey captured center-level data covering infrastructure, human resources, diagnostic and therapeutic availability, and clinical research activity. Data were analyzed using descriptive methods. Results: A total of 73 hematology centers from 16 Latin American countries completed the survey. Most centers were public institutions (53%), with a median number of four hematologists per center (range, 2-10). While basic pathology and flow cytometry were widely available, access to advanced diagnostics was limited. Fifteen centers (21%) lacked immunohistochemistry, and pathology turnaround times exceeded 3 weeks in 56%. Positron emission tomography-computed tomography was available in 41% of centers. Novel therapies such as antibody-drug conjugates, bispecific antibodies, and checkpoint inhibitors were not available or restricted in most centers. Hematopoietic stem-cell transplantation was performed in 41% of centers, whereas commercial CAR-T was available in 5%. Clinical trials were conducted in 34% of centers. Conclusion: Our findings highlight striking disparities between guideline-recommended lymphoma care and real-world institutional capacity across LATAM, underscoring the importance of collaborative efforts in building capacity and advocating for equitable access.This publication has 29 references indexed in Scilit:
- Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐upHemaSphere, 2025
- Access to novel cancer medicines in Europe: inequities across countries and their driversESMO Open, 2025
- Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2025
- Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: A worldwide cross-sectional survey by the worldwide network for blood and marrow transplantation (WBMT)Current Research in Translational Medicine, 2025
- Integrating Social Work Throughout the Hematopoietic Cell Transplantation Trajectory to Improve Patient and Caregiver OutcomesTransplantation and Cellular Therapy, 2025
- ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 updateAnnals of Oncology, 2025
- Training in Transplantation and Cellular Therapy in Latin America: A Cross-Sectional Study of the LABMTTransplantation and Cellular Therapy, 2024
- Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional surveyThe Lancet Oncology, 2021
- The state of haematopoietic cells transplantation in Latin AmericaThe Lancet Haematology, 2021
- Improving access to high‐cost cancer drugs in Latin America: Much to be doneCancer, 2017